untitled
|
|
|
- さあしゃ あみおか
- 5 years ago
- Views:
Transcription
1 (DDS)( ) DDS Drug Delivery System (pulmonary drug-delivery) Aradigm AERx AERx 3 3 Novo Nordisk NEDO AERx
2 1 Aradigm AERx (a) (b) (Aradigm Web ) (a) (b) Nektar 4 (Exubera) Nektar (inhaled amikacin) Alkermes 5 AIR Alkermes AIR Aerogen 6 SC GE 3M 7 6, M (3M Web ) 4 Nektar 5 Alkermes 6 Aerogen 7 3M iontech/ 2
3 Alexza Pharmaceuticals 8 Staccato ,000 (agitation) (Staccato loxapine) 3 Next Safety (2) (surface modification) Abbott ABSORB 13 Abbott Lancet ABSORB 3 Abbot ABSORB (Abbot Web ) REVA Medical Alexza Pharmaceuticals 9 Next Safety DES (Drug eluting stent) 13 Abbott ABSORB Press_Release_0588.htm 14 REVA Medical 3
4 15 MIV Therapeutics (3) (Ophthalmic delivery) InSite Vision 18 DuraSite AzaSite AzaSiteDuraSite (blepharoconjunctivitis) AzaSite Plus InSite Vision AzaSite ( ) (Insite Vision Web ) MIV Therapeutics 17 (bioavailability) 18 InSite Vision 4
5 Novagali Pharma 19 Novasorb Eyeject Nova63035 FDA IND 20 (4) (Iontophoresis) 21 Vyteris 22 Vyteris Smart Patch Smart Patch 5 vyteris LidoSite ( ) ( ) LidoSite (vyteris Web ) Alza 23 E-TRANS Transdermal 3 IOMed Novagali Pharma 20 IND (investigational new drug) INDA Investigational New Drug Application IND FDA Vyteris 23 Alza 24 IOMed 5
6 Hybresis 25 Ocuphor (5) Abraxis Bioscience FDA ABRAXANE ABRAXANE 27 (mucus layer) Elan Drug Technologies nm 6cm 2 12cm 2 24cm 2 6 (GRAS:Generally Regarded As Safe) (Elan Drug Technologies Web ) Abraxis Bioscience Elan Drug Technologies 6
7 Elan (NanoCrystal) Paliperidone Palmitate (NDA) FDA 4 29 NEC (6) (open a door) NEDO No
8 (7) Osel ) 2) MucoCept Osel 2 3 CDACTIN-O CDACTIN-O MIYA-BM Osel Biophage Pharma 35 Biophage Pharma (8) (Gene therapy vectors) 36 Calando Pharmaceuticals RNAi RNAi FDA (IND) sirna 33 Osel 34 (microflora) 35 Biophage Pharma =12&Itemid=
9 Neurologix FDA 2 Oxford BioMedica 38 LentiVector Oxford BioMedica TroVax 3 T 5T4 MVA 5T4 7 TroVax TroVax 5T4 5T4 T TroVax 5T4 MVA T 5T4 (Oxford BioMedica Web ) 37 Neurologix 38 Oxford BioMedica 9
10 Benda Pharmaceutical 39 Ebei GMP 40 Ebei Gendicine p53 (9) (nanoencapsulation) 41 (flash nanoprecipitation) (NIST) NISTI 2008 (microfluidics) Benda Pharmaceutical GMP: Good Manufacturing Practice Microfluidics cm 44 Point of care (POC) 10
11 (SRI Consulting Business Intelligence Explorer Program) NEDO 11
Microsoft Word - No1025_現＿一括ファイル（仮）.doc
ISSN 1348-5350 2008.7.2 BIWEEKLY 1025 NEDO 海外レポート 212-8554 神奈川県川崎市幸区大宮町 1310 ミューザ川崎セントラルタワー http://www.nedo.go.jp Ⅰ. テーマ特集 - ライフサイエンス バイオテクノロジー - 1. 薬剤送達システム (DDS) の開発 商品化状況 ( 世界 ) 1 2. パーソナライズドメディスン (
<4D F736F F F696E74202D F188C48F91817A C E7390EC816A2E B8CDD8AB B83685D>
2017 35,487 97.2 95.7 2017 2016 GOOD POINT WEAK POINT 2017 1 2 8,100 26,000 5 110,000 500 5 22,000 10 215,000 1,000 10 21,500 25 525,000 2,500 25 21,000 50 1,025,000 5,000 50 20,500 100 1,950,000
untitled
FK506 FK506 2005 17 4 1 1,2) 1 1943 18 12 1944 9 11 1946 4 2 11 J. W. 1948 26 2 1949 11 19511954 E-mail: michio.yamashita@astellas.com 2013 3 141 1956 4 1 10 1 1961 10 NRDC C CC CC CC CC CCNa 1962 7-7ACA
<B54CB5684E31A4E9C0CBA4E5AA6BC160BEE3B27AA544A5552E706466>
N1 2 3 1 16 17 18 19 20 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 4 2 38 39 40 41 42 44 45 46 47 48 50 51 52 53 54 55 56 57 58 59 60 61 5 3 62 63 64 65 66 68 69 70 70 72 74 75 76 77 78 80 81 82 83
起業本-入稿.indd
78 80 82 84 86 88 1 2 3 4 5 6 90 94 96 98 100 102 104 7 8 9 10 11 12 13 Contents 126 128 1 2 Contents 130 132 134 136 138 140 3 4 5 6 1 142 144 148 150 152 154 2 3 4 5 6 Contents 174 176 180 184 186 1
SRI106-5.indd
SRI 2012.3 No.106 237 SRI 2012.3 No.106 238 SRI 2012.3 No.106 239 240 SRI 2012.3 No.106 SRI 2012.3 No.106 241 242 SRI 2012.3 No.106 SRI 2012.3 No.106 243 244 SRI 2012.3 No.106 SRI 2012.3 No.106 245 246
1 93 1. 2. 3.
16 1 93 1. 2. 3. 2 93 4. 5. 17 6. 7. 3 93 4 93 5 93 6 93 ( ) 7 93 8 93 9 93 10 93 11 93 12 93 16 12 24 13 93 1 1 1 14 93 15 93 5 16 93 17 93 50% 50% 18 93 2.5% 0.25% 1/2(= 2 1 1 25 19 93 20 93 21 93 22
NEXT 1 2 3 1 2 3 4 5 6 1 2 1 2 1 1 1 1 2 3 1 2 3 4 5 6 1 2 3 4 1 2 3 4 5 6 1 2 3 4 5 1 2 3 1 1 2 1 2 3 4 5 6 7 1 2 3 1 2 1 2 3 4 5 6 7 8 9 1 1 1 2 1 2 1 2 3 4 5 6 1 2
2002 715 02-13M 1. 200110 024 2. 3. 4. 100 60 5. 6. 2002715 1 1 1 4 9 9 12 12 13 14 14 15 15 17 17 18 22 22 23 25 25 25 29 200110 024 3 1 1965 500 800 3,000 2,000 1 1 60 2.84 1.173 1 2002 71 1,726 1,085
ｽﾗｲﾄﾞ ﾀｲﾄﾙなし
2395 20 3 2008 5 16 SHIN NIPPON BIOMEDICAL LABORATORIES,LTD. 1 2 CONTENTS. 20 3 CFO. 2008 CEO... Translational Translational 3 . 20 3 CFO 4 20 3 P/L 19 3 20 3 17,289 19,500 19,647 +2,358 +147 1,125 1,453
損保ジャパンの現状2011
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 62 63 64 65 66 67 68 69
1
1 1. 2 1-1. 2 3 1-2.2 4 2. 5 6 7 2-1 2-2 2-3 2-4 2-5 2-1 2-2 2-3 2-4 2-5 PDF PDF 8 P10 9 2-1. 10 2-1. 11 2-1. ( ( 12 2-1. 24 13 2-1. 3 3 14 2-1. 15 2-2. 16 17 2-2. 3 18 2-2. 19 2712 3 1000 20 2841 21 ...
p01.qxd
2 s 1 1 2 6 2 POINT 23 23 32 15 3 4 s 1 3 2 4 6 2 7003800 1600 1200 45 5 3 11 POINT 2 7003800 7 11 7003800 8 12 9 10 POINT 2003 5 s 45700 3800 5 6 s3 1 POINT POINT 45 2700 3800 7 s 5 8 s3 1 POINT POINT
株主通信：第18期 中間
19 01 02 03 04 290,826 342,459 1,250,678 276,387 601,695 2,128,760 31,096 114,946 193,064 45,455 18,478 10,590 199,810 22,785 2,494 3,400,763 284,979 319,372 1,197,774 422,502 513,081 2,133,357 25,023
1003shinseihin.pdf
1 1 1 2 2 3 4 4 P.14 2 P.5 3 P.620 6 7 8 9 10 11 13 14 18 20 00 P.21 1 1 2 3 4 5 2 6 P7 P14 P13 P11 P14 P13 P11 3 P13 7 8 9 10 Point! Point! 11 12 13 14 Point! Point! 15 16 17 18 19 Point! Point! 20 21
ワタベウェディング株式会社
1 2 3 4 140,000 100,000 60,000 20,000 0 0 5 10 15 20 25 30 35 40 45 50 55 60 65 70 5 6 71 2 13 14 7 8 9 10 11 12 1 2 2 point 1 point 2 1 1 3 point 3 4 4 5 6 point 4 point 5 point 6 13 14 15 16 point 17
untitled
1 2 3 4 5 6 7 Point 60,000 50,000 40,000 30,000 20,000 10,000 0 29,979 41,972 31,726 45,468 35,837 37,251 24,000 20,000 16,000 12,000 8,000 4,000 0 16,795 22,071 20,378 14 13 12 11 10 0 12.19 12.43 12.40
株主通信 第16 期 報告書
10 15 01 02 1 2 3 03 04 4 05 06 5 153,476 232,822 6,962 19,799 133,362 276,221 344,360 440,112 412,477 846,445 164,935 422,265 1,433,645 26,694 336,206 935,497 352,675 451,321 1,739,493 30,593 48,894 153,612
![[商品カタログ]ゼンリン電子地図帳Ｚｉ16](/thumbs/48/24409875.jpg "[商品カタログ]ゼンリン電子地図帳Ｚｉ16")
ヤフー株式会社 株主通信VOL.16
01 260,602264,402 122,795125,595 64,84366,493 107110 120,260123,060 0 500 300 400 200 100 700 600 800 39.8% 23.7% 36.6% 26.6% 21.1% 52.4% 545 700 0 50 200 150 100 250 300 350 312 276 151 171 02 03 04 POINT
-- 0 500 1000 1500 2000 2500 3000 () 0% 20% 40% 60%23 47.5% 16.0% 26.8% 27.6% 10,000 -- 350 322 300 286 250 200 150 100 50 0 20 21 22 23 24 25 26 27 28 29 -- ) 300 280 260 240 163,558 165,000 160,000
WebIntellTN02.qxp (Page 1)
2004 Check Point Software Technologies Ltd. 1 2004 Check Point Software Technologies Ltd. 2 Webサーバ Webアプリケーション データベース Webアプリケーション データベース 2004 Check Point Software Technologies Ltd. 3 2004 Check Point Software
CEO 2017.10.30 Agenda Agenda ) 2000 2000 10 ~ ~ GLP: Good Laboratory Practice GCP: Good Clinical Practice GMP: Good Manufacturing Practice GPSP: Good Post-marketing Study 1 10,000 Practice GLP GMP GCP
<4D6963726F736F667420576F7264202D2081A193B98BE257656290EA97708CFB8DC08B4B92E88179918D8D878CFB8DC0817A816990568B4B816A81798A6D92E894C5817A2E646F63>
夏目小兵衛直克
39(1906)1222 14(1817) 3(1832)1514(1843) 2628 6 (1853) (1854)3727 3(1856) 1 / 13 5(1858)6(1859) 5(1853) () () () () () () 3(1867)29 504111( 2 / 13 )98 23 18 2(1869)310283 100 50() 58 226 3313200982 5033
nenkin.PDF
1 31 1 WEB 10 3,544 429 13 10 22 11 7 WEB 1 2 41.0 15 80.0 20 46.7% 1000 55.8 1000 34.4 21 18.2 1000 23 25 41.0 49.2 29 90.6 42.7 33 56.4% 79.2% 67.4 51.7 37 39 83.7 1 91.0 93.6 9 2 3 1000 96.3 300 1000
-1-
-1- -2- -3-1 8 6% 2 4 6 8 1 48 63 43 6 55 38 78 58 2 88 67 11 22 78 1 56 22 89 47 34 36 32 38 4 34 26 7 -4- 18-5- 3 25 28 (6.%) (6.%) (.9%) 2 15 18 158 1 (3.8%) (56.4%) 5 2 137 27 8 1 68 119 26 71 28 65
( )
Web Web 1 3 1 21 11 22 23 24 3 2 3 4 5 1 1 11 22 9 2 3 15 11 22 2 11 21 4 5 ( ) 102 ( ) 1 ( 1 2001 Web 1 5 4 1 1 - 7 - [] - 7 10 11 12 12 1 10 1 12 - [] 1 1 2 Q1 Q2 Q3 Q4 Q5 Q6 Q7 Q8 Q9 Q10 3 1 47
180 30 30 180 180 181 (3)(4) (3)(4)(2) 60 180 (1) (2) 20 (3)
12 12 72 (1) (2) (3) 12 (1) (2) (3) (1) (2) (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (1) (2) 180 30 30 180 180 181 (3)(4) (3)(4)(2) 60 180 (1) (2) 20 (3) 30 16 (1) 31 (2) 31 (3) (1) (2) (3) (4) 30
... 6 1) 2) No. 01 02 03 04 05 06 07 08 09 10 11 12 No. 1 2 2 3 3cm 4 untitled
1....1 2....2 2.1...2 2.2...2 3....14 3.1...14 3.2...14 4....15 4.1...15 4.2...18 4.3...21 4.4...23 4.5...26 5....27 5.1...27 5.2...35 5.3...54 5.4...64 5.5...75 6....79 6.1...79 6.2...85 6.3...94 6.4...
113 120cm 1120cm 3 10cm 900 500+240 10 1 2 3 5 4 5 3 8 6 3 8 6 7 6 8 4 4 4 4 23 23 5 5 7
untitled
21 14 487 2,322 2 7 48 4 15 ( 27) 14 3(1867) 3 () 1 2 3 ( 901923 ) 5 (1536) 3 4 5 6 7 8 ( ) () () 9 10 21 11 12 13 14 16 17 18 20 1 19 20 21 22 23 21 22 24 25 26 27 28 22 5 29 30cm 7.5m 1865 3 1820 5
1948 1907 4024 1925 14 19281929 30 111931 4 3 15 4 16 3 15 4 161933 813 1935 12 17 11 17 1938 1945 2010 14 221 1945 10 1946 11 1947 1048 1947 1949 24
15 4 16 1988 63 28 19314 29 3 15 4 16 19283 15294 16 1930 113132 3 15 4 16 33 13 35 12 3 15 4 16 1945 10 10 10 10 40 1948 1907 4024 1925 14 19281929 30 111931 4 3 15 4 16 3 15 4 161933 813 1935 12 17 11
裁定審議会における裁定の概要 (平成23年度)
23 23 23 4 24 3 10 11 12 13 14 () 1 23 7 21 23 12 14 (19 ) 30 1.876% 60 8 24 19 78 27 1 (10) 37 (3) 2 22 9 21 23 5 9 21 12 1 22 2 27 89 10 11 6 A B 3 21 12 1 12 10 10 12 5 1 9 1 2 61 ( 21 10 1 11 30 )
<91E6825289F1938C966B95FA8ECB90FC88E397C38B5A8F708A778F7091E589EF8EC08D7388CF88F5837D836A83858341838B566572312E696E6464>
Microsoft Word - 入居のしおり.doc
1 1 2 2 2 3 2 4 3 5 3 6 3 7 3 8 4 1 7 2 7 3 7 4 8 5 9 6 9 7 10 8 10 9 11 10 11 11 11 12 12 13 13 1 14 2 17 3 18 4 19 5 20 6 22 (1) 24 (2) 24 (3) 24 (4) 24 (5) 24 (6) 25 (7) 25 (8) 25 (9) 25 1 29 (1) 29
和県監査H15港湾.PDF
...1...1...1...1...1...1...1...1...2...2...2...3...3...3...5...5...10...11...12...13...13...13...14...14...14...14...14...14...15...15...15...15...15 ...16...17 14...17...18...18...19...21...23 2...25...27...27...28...28...28
( )
( ) () () 3 cm cm cm cm cm cm 1000 1500 50 500 1000 1000 1500 1000 10 50 300 1000 2000 1000 1500 50 10 1000 2000 300 50 1000 2000 1000 1500 50 10 1000 2000 300 30 10 300 1000 2000 1000 1500 1000
2002 (1) (2) (3) (4) (5) (1) (2) (3) (4) (5) (1) (2) (3) (4) (5) (6) (7) (8) (1) (2) (3) (4) (1) (2) (3) (4) (5) (6) (7) (8) No 2,500 3 200 200 200 200 200 50 200 No, 3 1 2 00 No 2,500 200 7 2,000 7
-26-
-25- -26- -27- -28- -29- -30- -31- -32- -33- -34- -35- -36- -37- -38- cm -39- -40- 1 2 3 4 4 3 2 1 5 5-41- -42- -43- -44- -45- -46- -47- -48- -49- -50- cm -51- -52- -53- -54- -55- -56- -57- -58- -59- -60-
